Artificial Intelligence

#Artificial intelligence (AI) #Collaboration #Drug discovery #Peptides

AI-powered platform could accelerate peptide drug discovery

CRDMO BioDuro and Atombeat have announced a strategic collaboration on an AI powered platform for accelerated peptide drug discovery.  The collaboration brings together Atombeat’s in silico modeling, AI-accelerated and data-driven design platform with BioDuro’s discovery chemistry, biology and DMPK.  The combined platform aims… Read More

#News

#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #DMTA #Drug discovery

AI-augmented innovation: Enabling DMTA with digital-physical synergy

Andrew Anderson, Vice President, Innovation and Informatics Strategy at ACD/Labs, looks at how AI is enabling true drug design. Innovators in the pharma and biopharma sectors are actively seeking systems that accelerate the discovery, development, and commercialisation of new products. Of particular interest are systems to support the implementation of… Read More

#Exclusive Content

Scientist using a laptop
#Artificial intelligence (AI) #Biopharma #Computational chemistry #Events #Pathology #Webinar

Webinar: Hear from companies at the forefront of digital pathology

Digital pathology and AI are fundamentally transforming how biopharma companies discover, develop, and deliver life-changing medicines. As a result, today’s leaders aren’t debating whether to invest in digital pathology—they’re racing to scale it, unlocking faster breakthroughs, smarter clinical trials, and broader patient access to next-generation therapies. Organisations that move quickly… Read More

Webinar date:
Sponsored by Proscia
#News

#Antisense Oligonucleotides (ASOs) #Artificial intelligence (AI) #Genetics / genomics #RNA

Advances in RNA therapeutics with CAMP4

DDW Editor Reece Armstrong speaks to Josh Mandel-Brehm, CEO of CAMP4 Therapeutics, about challenges in the discovery and development of RNA therapeutics. RA: Why has regulatory RNA historically not been exploited as a therapeutic target?  JMB: Historically, RNA has been viewed primarily as a messenger — a passive intermediary between… Read More

#Exclusive Content

#Artificial intelligence (AI) #CRISPR #Gene editing #Genetics / genomics #Large language model (LLM)

Stanford team creates AI gene editing tool ‘CRISPR-GPT’

A team at Standford have created CRISPR-GPT, a large language model (LLM) agent system to automate and enhance CRISPR-based gene-editing design and data analysis.   CRISPR-GPT leverages the reasoning capabilities of LLMs for complex task decomposition, decision-making and interactive human–artificial intelligence (AI) collaboration.  The system incorporates… Read More

#Editor's Choice #News

Histology slides
#Artificial intelligence (AI) #Biopharma #Computational chemistry #Events #Pathology #Webinar

Webinar: Biopharma and the shift to computational pathology

Digital pathology and AI are fundamentally transforming how biopharma companies discover, develop, and deliver life-changing medicines. As a result, today’s leaders aren’t debating whether to invest in digital pathology—they’re racing to scale it, unlocking faster breakthroughs, smarter clinical trials, and broader patient access to next-generation therapies. Organisations that move quickly… Read More

Webinar date:
Sponsored by Proscia
#News

#Artificial intelligence (AI) #Neuroscience #Supercomputing

How advances in neuroscience can be powered by AI and supercomputing

DDW Editor Reece Armstrong sits down with Tarek Samad, Lundbeck’s Senior Vice President and Head of Research to discuss AI and supercomputing within the drug discovery industry following the company’s recent agreement with the Danish Centre for AI Innovation (DCAI). In May this year, Lundbeck announced an agreement with the… Read More

#Exclusive Content

Diffuse large B-cell lymphoma
#Artificial intelligence (AI) #Lantern Pharma #Lymphoma #Oncology #Orphan drugs #Phase I trial

Complete response in heavily pre-treated lymphoma patient

A heavily pretreated patient with aggressive Grade 3 non-germinal centre diffuse large B-cell lymphoma (DLBCL) achieved a complete metabolic response in the ongoing Phase I clinical trial of Lantern Pharma’s LP-284.  Lantern uses an AI approach to determine mechanisms of action of any cancer focused molecule, identify… Read More

#Cancer Research #Editor's Choice #News

Computer in laboratory
#Artificial intelligence (AI) #Biopharma #Computational chemistry #Events #Pathology #Webinar

Webinar: How pathology AI is transforming biopharma R&D

Digital pathology and AI are fundamentally transforming how biopharma companies discover, develop, and deliver life-changing medicines. As a result, today’s leaders aren’t debating whether to invest in digital pathology—they’re racing to scale it, unlocking faster breakthroughs, smarter clinical trials, and broader patient access to next-generation therapies. Organisations that move quickly… Read More

Webinar date:
Sponsored by Proscia
#News

Artificial intelligence
#AI / data analytics / healthtech / informatics #Antibodies #Antibody-based therapeutics #Artificial intelligence (AI) #Clinical trial design #Clinical trials #Start-ups

New podcast: Innovative applications of AI in drug discovery

This is the latest episode of the free DDW narrated podcast, titled “Innovative applications of AI in drug discovery”, which covers two articles written for DDW Volume 24 – Issue 4, Fall 2023. They are called: “Decoding diseases: The AI renaissance in clinical trials” and “Advancing antibody… Read More

#News

Digital pathology
#Artificial intelligence (AI) #Biopharma #Computational chemistry #Events #Pathology #Webinar

Webinar: The strategic power of pathology and AI for biopharma R&D

Digital pathology and AI are fundamentally transforming how biopharma companies discover, develop, and deliver life-changing medicines. As a result, today’s leaders aren’t debating whether to invest in digital pathology—they’re racing to scale it, unlocking faster breakthroughs, smarter clinical trials, and broader patient access to next-generation therapies. Organisations that move quickly… Read More

Webinar date:
Sponsored by Proscia
#News

Human neuron
#Age-related diseases (ARDs) #Artificial intelligence (AI) #Biochemistry #Biotechnology #Integrated Biosciences #Neuroscience #Optogenetics

New optogenetic screening platform for drug discovery

Integrated Biosciences, a biotechnology company integrating optogenetics, chemistry and AI to discover small molecule therapeutics for age-related diseases, has published a study in Cell, introducing its optogenetic screening platform. According to the paper, the platform allows for precise and dynamic control of biological targets and processes, unlocking a powerful new… Read More

#News

#Artificial intelligence (AI) #Biopharma #Biotechnology #Drug discovery #Genetics / genomics

DDW Summer edition – out now!

The DDW Summer issue is available to read now. It features in-depth articles on the technologies and advancements driving genomics drug discovery, how supercomputing can drive neuroscience discoveries, and everything you need to know about spatial biology.  Other features include:   A market report on… Read More

#Editor's Choice #News

Sickle cells
#Artificial intelligence (AI) #Cellarity #Phase I trial #Sickle cell disorder (SCD) #Transcriptomics

Globin-Switching drug reduces sickle cell disease symptoms

Biotech Cellarity has dosed its first patient in a Phase I clinical trial of CLY-124, a first-in-class Globin-Switching oral medicine designed to treat sickle cell disease (SCD).   “Initiation of our first-in-human clinical study for CLY-124 represents the delivery of our first clinical asset from our platform with… Read More

#News

Seed fund
#Artificial intelligence (AI) #Drug discovery #Genetics / genomics #OutSee #Seed funding #Start-ups

Predictive genomics pioneer OutSee raises £1.8m

OutSee has secured £1.8 ($2.4) million in seed funding, led by Ahren Innovation Capital and with additional investment from Kadmos Capital, Empirical Ventures and Panacea Ventures.   The funds will support OutSee through the next phase of its growth strategy, with a focus on expanding the company’s in-house target discovery programme… Read More

#Business & Investment #News #Start-up Zone

#Artificial intelligence (AI) #Clinical trial design #Drug discovery #Lab technology #SLAS

New DDW Highlights podcast: 30 June 2025

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. As we announce the DDW ‘Creating cures’ programme at SLAS2026, the week’s news highlights emphasise… Read More

#News